<?xml version="1.0" encoding="UTF-8" ?><rss version="2.0">
	<channel>
	    <title><![CDATA[Vascular Health and Risk Management]]></title>
	    <description><![CDATA[Official journal of the International Society of Vascular Health (ISVH)Indexed:EMBase, EMCare, Scopus and the Elsevier Bibliographic databasesAmerican Chemical Society&#39;s &#39;Chemical Abstracts Service&#39; (CAS)MedLinePubMed Central (title abbreviation Vasc Health Risk Manag)OAIster: The Open Access InitiativeIndex CopernicusICAAP (International Consortium for the Advancement of Academic Publication)ResearchGATE scientific networkISSN 1176-6344 (Print)ISSN 1178-2048 (Online)An international, peer-reviewed journal of therapeutics and risk management, focusing on concise rapid reporting of clinical studies on the processes involved in the maintenance of vascular health; the monitoring, prevention, and treatment of vascular disease and its sequelae; and the involvement of metabolic disorders, particularly diabetes. In addition, the journal will also seek to define drug usage in terms of ultimate uptake and acceptance by the patient and healthcare professional.Key BenefitsConcise rapid reportingClinical therapeutics and pharmacology focusCardiovascular and metabolic disordersAims and scopeSubject areas include:Endothelial function, inflammation, biochemical and cellular processes, markers, coagulation disorders, and thromboembolism Lipid metabolism and dyslipidemia Metabolic disorders, such as diabetes, and their impact on vascular health Stroke, heart failure, atherosclerosis, coronary artery disease, hypertension, peripheral vascular disease, pulmonary embolism, and diabetic involvement in nephropathy and retinopathy Screening and prevention studies Risk factor analyses Clinical studies of compounds used in the management of cardiovascular and metabolic disorders (clinical trials, pharmacodynamic, kinetic reports), including individual compounds, combinations, and new formulations Studies in specific populations, particularly the elderly and at-risk populations Safety and postmarketing surveillance studies, outcome studies, and economic analyses of drug treatment and disease, including modeling Drug management of specific diseases, clinical guidelines, formulary management Risk management programs, patient and health education programs and studies. These areas are addressed through:Original research (full papers and concise rapid reports)Reviews Systematic reviews of individual new or important drugs where a change in therapeutic management of a disease may be indicatedExpert opinion and commentary.]]></description>
	    <link>http://dovepress.com/vascular-health-and-risk-management-journal</link>
	    			<item>
    			<title><![CDATA[Management of acute attacks of hereditary angioedema: potential role of icatibant]]></title>
				<description><![CDATA[Hilary J Longhurst ]]></description>
				<link>http://dovepress.com/management-of-acute-attacks-of-hereditary-angioedema-potential-role-of-peer-reviewed-article-VHRM</link>
				<guid isPermaLink="true">http://dovepress.com/management-of-acute-attacks-of-hereditary-angioedema-potential-role-of-peer-reviewed-article-VHRM</guid>
			</item>
	    			<item>
    			<title><![CDATA[Triple combination therapy with amlodipine, valsartan, and hydrochlorothiazide vs dual combination therapy with amlodipine and hydrochlorothiazide for stage 2 hypertensive patients]]></title>
				<description><![CDATA[Maurizio Destro, Nora Crikelair, Joseph Yen, et al.]]></description>
				<link>http://dovepress.com/triple-combination-therapy-with-amlodipine-valsartan-and-hydrochloroth-peer-reviewed-article-VHRM</link>
				<guid isPermaLink="true">http://dovepress.com/triple-combination-therapy-with-amlodipine-valsartan-and-hydrochloroth-peer-reviewed-article-VHRM</guid>
			</item>
	    			<item>
    			<title><![CDATA[Role of endothelin receptor A and NADPH oxidase in vascular abnormalities]]></title>
				<description><![CDATA[De-Zai Dai, Yin Dai]]></description>
				<link>http://dovepress.com/role-of-endothelin-receptor-a-and-nadph-oxidase-in-vascular-abnormalit-peer-reviewed-article-VHRM</link>
				<guid isPermaLink="true">http://dovepress.com/role-of-endothelin-receptor-a-and-nadph-oxidase-in-vascular-abnormalit-peer-reviewed-article-VHRM</guid>
			</item>
	    			<item>
    			<title><![CDATA[Argatroban in the management of heparin-induced thrombocytopenia]]></title>
				<description><![CDATA[Luciano Babuin, Vittorio Pengo]]></description>
				<link>http://dovepress.com/argatroban-in-the-management-of-heparin-induced-thrombocytopenia-peer-reviewed-article-VHRM</link>
				<guid isPermaLink="true">http://dovepress.com/argatroban-in-the-management-of-heparin-induced-thrombocytopenia-peer-reviewed-article-VHRM</guid>
			</item>
	    			<item>
    			<title><![CDATA[Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice]]></title>
				<description><![CDATA[Peter Bramlage, Wolf-Peter Wolf, Thomas Stuhr, et al]]></description>
				<link>http://dovepress.com/effectiveness-and-tolerability-of-a-fixed-dose-combination-of-olmesart-peer-reviewed-article-VHRM</link>
				<guid isPermaLink="true">http://dovepress.com/effectiveness-and-tolerability-of-a-fixed-dose-combination-of-olmesart-peer-reviewed-article-VHRM</guid>
			</item>
	    			<item>
    			<title><![CDATA[Levosimendan neither improves nor worsens mortality in patients with cardiogenic shock due to ST-elevation myocardial infarction]]></title>
				<description><![CDATA[Elmir Omerovic, Truls R&aring;munddal, Per Albertsson, et al]]></description>
				<link>http://dovepress.com/levosimendan-neither-improves-nor-worsens-mortality-in-patients-with-c-peer-reviewed-article-VHRM</link>
				<guid isPermaLink="true">http://dovepress.com/levosimendan-neither-improves-nor-worsens-mortality-in-patients-with-c-peer-reviewed-article-VHRM</guid>
			</item>
	    			<item>
    			<title><![CDATA[Effectiveness of percutaneous laser revascularization therapy for refractory angina]]></title>
				<description><![CDATA[Michael McGillion, Allison Cook, J Charles Victor, et al]]></description>
				<link>http://dovepress.com/effectiveness-of-percutaneous-laser-revascularization-therapy-for-refr-peer-reviewed-article-VHRM</link>
				<guid isPermaLink="true">http://dovepress.com/effectiveness-of-percutaneous-laser-revascularization-therapy-for-refr-peer-reviewed-article-VHRM</guid>
			</item>
	    			<item>
    			<title><![CDATA[Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review]]></title>
				<description><![CDATA[Suzanne A Ligthart, Eric P Moll van Charante, Willem A Van Gool, et al]]></description>
				<link>http://dovepress.com/treatment-of-cardiovascular-risk-factors-to-prevent-cognitive-decline--peer-reviewed-article-VHRM</link>
				<guid isPermaLink="true">http://dovepress.com/treatment-of-cardiovascular-risk-factors-to-prevent-cognitive-decline--peer-reviewed-article-VHRM</guid>
			</item>
	    			<item>
    			<title><![CDATA[Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization]]></title>
				<description><![CDATA[Richard Kones]]></description>
				<link>http://dovepress.com/recent-advances-in-the-management-of-chronic-stable-angina-ii-anti-isc-peer-reviewed-article-VHRM</link>
				<guid isPermaLink="true">http://dovepress.com/recent-advances-in-the-management-of-chronic-stable-angina-ii-anti-isc-peer-reviewed-article-VHRM</guid>
			</item>
	    			<item>
    			<title><![CDATA[Urotensin II-induced signaling involved in proliferation of vascular smooth muscle cells]]></title>
				<description><![CDATA[Myriam Iglewski, Stephen R Grant]]></description>
				<link>http://dovepress.com/urotensin-ii-induced-signaling-involved-in-proliferation-of-vascular-s-peer-reviewed-article-VHRM</link>
				<guid isPermaLink="true">http://dovepress.com/urotensin-ii-induced-signaling-involved-in-proliferation-of-vascular-s-peer-reviewed-article-VHRM</guid>
			</item>
	    			<item>
    			<title><![CDATA[Aliskiren and valsartan combination therapy for the management of hypertension]]></title>
				<description><![CDATA[Benjamin J Epstein]]></description>
				<link>http://dovepress.com/aliskiren-and-valsartan-combination-therapy-for-the-management-of-hype-peer-reviewed-article-VHRM</link>
				<guid isPermaLink="true">http://dovepress.com/aliskiren-and-valsartan-combination-therapy-for-the-management-of-hype-peer-reviewed-article-VHRM</guid>
			</item>
	    			<item>
    			<title><![CDATA[Role of olmesartan in combination therapy in blood pressure control and vascular function]]></title>
				<description><![CDATA[Carlos M Ferrario, Ronald D Smith]]></description>
				<link>http://dovepress.com/role-of-olmesartan-in-combination-therapy-in-blood-pressure-control-an-peer-reviewed-article-VHRM</link>
				<guid isPermaLink="true">http://dovepress.com/role-of-olmesartan-in-combination-therapy-in-blood-pressure-control-an-peer-reviewed-article-VHRM</guid>
			</item>
	    			<item>
    			<title><![CDATA[The utility of troponin measurement to detect myocardial infarction: review of the current findings]]></title>
				<description><![CDATA[Melissa A Daubert, Allen Jeremias]]></description>
				<link>http://dovepress.com/the-utility-of-troponin-measurement-to-detect-myocardial-infarction-re-peer-reviewed-article-VHRM</link>
				<guid isPermaLink="true">http://dovepress.com/the-utility-of-troponin-measurement-to-detect-myocardial-infarction-re-peer-reviewed-article-VHRM</guid>
			</item>
	    			<item>
    			<title><![CDATA[Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment]]></title>
				<description><![CDATA[Curtis Triplitt, Eugenio Cersosimo, Ralph A DeFronzo]]></description>
				<link>http://dovepress.com/pioglitazone-and-alogliptin-combination-therapy-in-type-2-diabetes-a-p-peer-reviewed-article-VHRM</link>
				<guid isPermaLink="true">http://dovepress.com/pioglitazone-and-alogliptin-combination-therapy-in-type-2-diabetes-a-p-peer-reviewed-article-VHRM</guid>
			</item>
	    			<item>
    			<title><![CDATA[Atherogenic dyslipidemia and diabetes mellitus: what&rsquo;s new in the management arena?]]></title>
				<description><![CDATA[Ajoy Kumar, Vibhuti Singh]]></description>
				<link>http://dovepress.com/atherogenic-dyslipidemia-and-diabetes-mellitus-whatrsquos-new-in-the-m-peer-reviewed-article-VHRM</link>
				<guid isPermaLink="true">http://dovepress.com/atherogenic-dyslipidemia-and-diabetes-mellitus-whatrsquos-new-in-the-m-peer-reviewed-article-VHRM</guid>
			</item>
	    			<item>
    			<title><![CDATA[Estimating glomerular filtration rate in a population-based study]]></title>
				<description><![CDATA[Anoop Shankar, Kristine E Lee, Barbara EK Klein, et al]]></description>
				<link>http://dovepress.com/estimating-glomerular-filtration-rate-in-a-population-based-study-peer-reviewed-article-VHRM</link>
				<guid isPermaLink="true">http://dovepress.com/estimating-glomerular-filtration-rate-in-a-population-based-study-peer-reviewed-article-VHRM</guid>
			</item>
	    			<item>
    			<title><![CDATA[MRI sagittal abdominal diameter is a stronger predictor of metabolic syndrome than visceral fat area or waist circumference in a high-risk vascular cohort]]></title>
				<description><![CDATA[Michel R Hoenig]]></description>
				<link>http://dovepress.com/mri-sagittal-abdominal-diameter-is-a-stronger-predictor-of-metabolic-s-peer-reviewed-article-VHRM</link>
				<guid isPermaLink="true">http://dovepress.com/mri-sagittal-abdominal-diameter-is-a-stronger-predictor-of-metabolic-s-peer-reviewed-article-VHRM</guid>
			</item>
	    			<item>
    			<title><![CDATA[Recent advances in the management of chronic stable angina I: Approach to the patient, diagnosis, pathophysiology, risk stratification, and gender disparities]]></title>
				<description><![CDATA[Richard Kones]]></description>
				<link>http://dovepress.com/recent-advances-in-the-management-of-chronic-stable-angina-i-approach--peer-reviewed-article-VHRM</link>
				<guid isPermaLink="true">http://dovepress.com/recent-advances-in-the-management-of-chronic-stable-angina-i-approach--peer-reviewed-article-VHRM</guid>
			</item>
	    			<item>
    			<title><![CDATA[Current and emerging therapeutic options for the treatment of chronic chagasic cardiomyopathy]]></title>
				<description><![CDATA[Claudio A Muratore, Adrian Baranchuk]]></description>
				<link>http://dovepress.com/current-and-emerging-therapeutic-options-for-the-treatment-of-chronic--peer-reviewed-article-VHRM</link>
				<guid isPermaLink="true">http://dovepress.com/current-and-emerging-therapeutic-options-for-the-treatment-of-chronic--peer-reviewed-article-VHRM</guid>
			</item>
	    			<item>
    			<title><![CDATA[Management of high-risk popliteal vascular blunt trauma: clinical experience with 62 cases]]></title>
				<description><![CDATA[Ali Pourzand, Bassir A Fakhri, Ramin Azhough, et al]]></description>
				<link>http://dovepress.com/management-of-high-risk-popliteal-vascular-blunt-trauma-clinical-exper-peer-reviewed-article-VHRM</link>
				<guid isPermaLink="true">http://dovepress.com/management-of-high-risk-popliteal-vascular-blunt-trauma-clinical-exper-peer-reviewed-article-VHRM</guid>
			</item>
	    			<item>
    			<title><![CDATA[Cardiac risk stratification: Role of the coronary calcium score]]></title>
				<description><![CDATA[Rakesh K Sharma, Rajiv K Sharma, Donald J Voelker, et al]]></description>
				<link>http://dovepress.com/cardiac-risk-stratification-role-of-the-coronary-calcium-score-peer-reviewed-article-VHRM</link>
				<guid isPermaLink="true">http://dovepress.com/cardiac-risk-stratification-role-of-the-coronary-calcium-score-peer-reviewed-article-VHRM</guid>
			</item>
	    			<item>
    			<title><![CDATA[Using noncontrast cardiac CT and coronary artery calcification measurements for cardiovascular risk assessment and management in asymptomatic adults]]></title>
				<description><![CDATA[John A Rumberger]]></description>
				<link>http://dovepress.com/using-noncontrast-cardiac-ct-and-coronary-artery-calcification-measure-peer-reviewed-article-VHRM</link>
				<guid isPermaLink="true">http://dovepress.com/using-noncontrast-cardiac-ct-and-coronary-artery-calcification-measure-peer-reviewed-article-VHRM</guid>
			</item>
	    			<item>
    			<title><![CDATA[Blood pressure-independent effect of candesartan on cardio-ankle vascular index in hypertensive patients with metabolic syndrome]]></title>
				<description><![CDATA[Kanako Bokuda, Atsuhiro Ichihara, Mariyo Sakoda, et al]]></description>
				<link>http://dovepress.com/blood-pressure-independent-effect-of-candesartan-on-cardio-ankle-vascu-peer-reviewed-article-VHRM</link>
				<guid isPermaLink="true">http://dovepress.com/blood-pressure-independent-effect-of-candesartan-on-cardio-ankle-vascu-peer-reviewed-article-VHRM</guid>
			</item>
	    			<item>
    			<title><![CDATA[Congestive heart failure in subjects with thyrotoxicosis in a black community]]></title>
				<description><![CDATA[R C Anakwue,&nbsp;B J C Onwubere, B C Anisiuba, et al]]></description>
				<link>http://dovepress.com/congestive-heart-failure-in-subjects-with-thyrotoxicosis-in-a-black-co-peer-reviewed-article-VHRM</link>
				<guid isPermaLink="true">http://dovepress.com/congestive-heart-failure-in-subjects-with-thyrotoxicosis-in-a-black-co-peer-reviewed-article-VHRM</guid>
			</item>
	    			<item>
    			<title><![CDATA[Clinical profile of hypertension at a University Teaching Hospital in Nigeria]]></title>
				<description><![CDATA[Arthur C Onwuchekwa, Sunday Chinenye]]></description>
				<link>http://dovepress.com/clinical-profile-of-hypertension-at-a-university-teaching-hospital-in--peer-reviewed-article-VHRM</link>
				<guid isPermaLink="true">http://dovepress.com/clinical-profile-of-hypertension-at-a-university-teaching-hospital-in--peer-reviewed-article-VHRM</guid>
			</item>
	        </channel>
</rss>